Frozen section is not cost beneficial for the assessment of margins in oral cancer.


Journal

Indian journal of cancer
ISSN: 1998-4774
Titre abrégé: Indian J Cancer
Pays: India
ID NLM: 0112040

Informations de publication

Date de publication:
Historique:
entrez: 6 4 2019
pubmed: 6 4 2019
medline: 3 8 2019
Statut: ppublish

Résumé

Routine use of frozen section (FS) is a costly procedure and sparsely available in resource poor countries. A proper cost benefit analysis may help to reduce its routine use and would empower surgeons to perform oral cancer surgeries without having FS facility. FS is performed to identify microscopic spread beyond gross disease that cannot be assessed clinically. Our primary aim was to determine the cost benefit analysis of FS in the assessment of margins in oral cavity squamous cell carcinoma (OSCC). Retrospective study of prospectively collected data of 1311 consecutive patients who were operated between January 2012 and October 2013. The gross and microscopic margin status of each patient was extracted from the patient's chart. The cost estimates were performed to calculate the financial burden of FS as well as expenses incurred on adjuvant treatment resulting from inadequate margins. Microscopic spread changed the gross margin status in 5.2% (65/1237) patients. Of this entire cohort of 1237 patients, FS helped 29 (2.3%) patients to achieve tumor free margin, and it changed the adjuvant treatment plan in 9 (0.7%) patients. The cost of FS for each patient was INR 11052. The cost-benefit ratio of FS was 12:1. Gross examination alone could have identified majority of the inadequate margins. Frozen section for assessment of margin status bears poor cost-benefit ratio. Meticulous gross examination of the entire surgical specimen is sufficient to identify majority of inadequate margins.

Sections du résumé

BACKGROUND BACKGROUND
Routine use of frozen section (FS) is a costly procedure and sparsely available in resource poor countries. A proper cost benefit analysis may help to reduce its routine use and would empower surgeons to perform oral cancer surgeries without having FS facility. FS is performed to identify microscopic spread beyond gross disease that cannot be assessed clinically.
OBJECTIVE OBJECTIVE
Our primary aim was to determine the cost benefit analysis of FS in the assessment of margins in oral cavity squamous cell carcinoma (OSCC).
MATERIALS AND METHODS METHODS
Retrospective study of prospectively collected data of 1311 consecutive patients who were operated between January 2012 and October 2013. The gross and microscopic margin status of each patient was extracted from the patient's chart. The cost estimates were performed to calculate the financial burden of FS as well as expenses incurred on adjuvant treatment resulting from inadequate margins.
RESULT RESULTS
Microscopic spread changed the gross margin status in 5.2% (65/1237) patients. Of this entire cohort of 1237 patients, FS helped 29 (2.3%) patients to achieve tumor free margin, and it changed the adjuvant treatment plan in 9 (0.7%) patients. The cost of FS for each patient was INR 11052. The cost-benefit ratio of FS was 12:1. Gross examination alone could have identified majority of the inadequate margins.
CONCLUSION CONCLUSIONS
Frozen section for assessment of margin status bears poor cost-benefit ratio. Meticulous gross examination of the entire surgical specimen is sufficient to identify majority of inadequate margins.

Identifiants

pubmed: 30950438
pii: IndianJournalofCancer_2019_56_1_19_255484
doi: 10.4103/ijc.IJC_41_18
doi:

Types de publication

Journal Article

Langues

eng

Pagination

19-23

Déclaration de conflit d'intérêts

There are no conflicts of interest.

Auteurs

Sourav Datta (S)

Department of Head and Neck Surgery, Tata Memorial Hospital, Mumbai, Maharashtra, India.

Aseem Mishra (A)

Department of Head and Neck Surgery, Tata Memorial Hospital, Mumbai, Maharashtra, India.

Pankaj Chaturvedi (P)

Department of Head and Neck Surgery, Tata Memorial Hospital, Mumbai, Maharashtra, India.

Munita Bal (M)

Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India.

Deepa Nair (D)

Department of Head and Neck Surgery, Tata Memorial Hospital, Mumbai, Maharashtra, India.

Yogesh More (Y)

Department of Head and Neck Surgery, Tata Memorial Hospital, Mumbai, Maharashtra, India.

Pranav Ingole (P)

Department of Head and Neck Surgery, Tata Memorial Hospital, Mumbai, Maharashtra, India.

Sandeep Sawakare (S)

Department of Medical Administration, Tata Memorial Hospital, Mumbai, Maharashtra, India.

Jai Prakash Agarwal (JP)

Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.

Shubhada V Kane (SV)

Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India.

Poonam Joshi (P)

Department of Head and Neck Surgery, Tata Memorial Hospital, Mumbai, Maharashtra, India.

Sudhir Nair (S)

Department of Head and Neck Surgery, Tata Memorial Hospital, Mumbai, Maharashtra, India.

Anil D'Cruz (A)

Department of Head and Neck Surgery, Tata Memorial Hospital, Mumbai, Maharashtra, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH